MedTrace Logo

A Study of Safety, Tolerability, and the Effects Two ND-L02-s0201 Have on the Body

NCT03241264 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2017-08-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability, and the effects two ND-L02-s0201 have on the body

Conditions

Interventions

DRUG

ND-L02-s0201

Specified dose on specified day

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-08-28
Primary Completion
2016-10-21
Completion
2016-10-21
FDA Drug
Yes

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03241264 on ClinicalTrials.gov